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In The Lancet Microbe, Paul Adepoju provides a report1 
on how Africa lags behind in the global race to rollout 
COVID-19 mass vaccination. This race is unprecedented 
and characterised by high-income countries adopting 
strategies such as pre-ordering millions of doses before 
the COVID-19 vaccines completed clinical trials. Africa 
has now embarked on the biggest immunisation drive 
in history with the aim of achieving 60% population 
coverage with the COVID-19 vaccine by June, 2022, 
through the WHO-led COVAX facility. Other continents 
appear to be far ahead, with Asia securing the 
commitment of the USA, Australia, India, and Japan to 
supply up to a billion COVID-19 vaccine doses across the 
continent by the end of 2022 and the Asian Development 
Bank to provide US$9 billion to the Asia Pacific Vaccine 
Access Facility to supply COVID-19 vaccines. These trends 
have resulted in the world’s poorest nations receiving 
only 0·2% of the 700 million COVID-19 vaccine doses 
by April, 2021, while more than 87% of global vaccine 
stocks have gone to high-income countries.2
This inequality gap is being addressed by strong 
multilateral cooperation involving the African Vaccine 
Acquisition Task Team of the African Union and the 
COVAX consortium with COVID-19 vaccines mostly 
produced in India.3 However, India’s recent export ban on 
COVID-19 vaccines in response to a surge in COVID-19 
cases has resulted in COVAX supplies running out in 
several African countries.
Adepoju also reports that additional doses of 
COVID-19 vaccines have been secured for Africa 
by the African Vaccine Acquisition Task Team from 
AstraZeneca, Pfizer, and Johnson & Johnson.1 Morocco 
adopted proactive vaccine supply policies by fast 
tracking approval for AstraZeneca, Sinopharm, and 
Sputnik V vaccines. A leading Egyptian pharmaceutical 
company has signed a deal to manufacture more than 
40 million doses of the Sputnik V vaccine annually 
in Cairo. Seychelles has also registered the Sputnik V 
vaccine as part of an emergency use authorisation.
Besides the complexity and interconnectedness of 
global supply chains, the effectiveness of vaccine rollout 
underway in Africa could be undermined by a familiar 
enemy—vaccine hesitancy. Vaccine hesitancy refers to 
a delay in the acceptance or blunt refusal of vaccines. 
This has been reported in several African countries and is 
linked to three factors. First, public distrust of government 
response to COVID-19; second, lack of community 
involvement in decision making on health issues; and 
third, minimal attempts to debunk misinformation 
about COVID-19 on social and traditional media.4 The 
problem of vaccine hesitancy is not new to Africa. A 
striking example is the polio vaccine boycott in Nigeria in 
2003–04, which, fuelled by distrust, quintupled the polio 
incidence in Nigeria between 2002 and 2006, leading 
to polio outbreaks across three continents.5 Vaccine 
hesitancy is, however, not limited to Africa as rumours 
and reports of severe blood coagulation problems 
following administration of the AstraZeneca vaccine in 
European countries interrupted use of this vaccine in 16 of 
these countries.6
Only 1% of the vaccines administered in Africa are 
produced by manufacturers based in five countries: 
Egypt, Morocco, Senegal, South Africa, and Tunisia.7,8 
On April 13, 2021, African leaders committed to an 
ambitious plan of building factories and supporting 
research and development to boost the share of 
vaccines manufactured in Africa from 1% in 2021 to 
60% by 2040. With the Africa Centre for Disease Control 
planning to establish five new vaccine-manufacturing 
centres across Africa and the African Development Bank 
pledging to finance at least two technology platforms 
worth US$400 million for vaccine production,1 the 
continent appears to making progress towards creating 
an indigenous vaccines industry.
However, vaccine manufacturing in Africa will 
require heavy long-term financing, government and 
stakeholder commitment to purchase manufactured 
vaccines, expanded research capacity, and strategic 
regulatory support and guidance. It is equally vital 
to establish supply networks to guarantee uptake 
of vaccines manufactured within the continent. The 
African Continental Free Trade Area that was launched 
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on Jan 1, 2021, to connect 1·2 billion people across 
54 countries holds great promise in this regard.
Technology innovation—including whole-genome 
sequencing9 to provide real-time information on the 
biology and evolution of infectious organisms—should 
be adopted to support vaccine development and 
manufacture in Africa to drive down production costs. 
New research from Africa indicates that combining 
genomic and epidemiological surveillance bolsters 
infectious disease outbreak response and containment.10 
This will be invaluable for identifying new variants of 
SARS-CoV-2, including the kappa (B.1.617.1) and delta 
(B.1.617.2) variants. Combining these approaches could 
better position Africa to mitigate the next pandemic by 
producing vaccines for its citizens.
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